Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On February 27, 2017, Accelerate Diagnostics, Inc. (the Company)
hosted a conference call to discuss its preliminary results of
operations for the quarter and fiscal year ended December 31,
2016. A copy of the transcript of the conference call is attached
hereto as Exhibit 99.1.
In accordance with General Instruction B.2 for Form 8-K, the
information in this Item 2.02, including Exhibit 99.1, shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
| Item 8.01. | Other Events. |
On February 23, 2017, the Company issued a press release
announcing the U.S. Food and Drug Administration granted the
Companys de novo request to market the Accelerate Pheno
system and Accelerate PhenoTest BC kit for identification and
antibiotic susceptibility testing of pathogens directly from
positive blood culture samples. A copy of the Companys press
release is attached hereto as Exhibit 99.2 and is incorporated
herein by reference in its entirety.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.The following materials are filed as exhibits to this
Current Report on Form 8-K:
| Exhibit | ||
| Number | Description | |
| 99.1 |
Preliminary Earnings Call Transcript, February 27, 2017 |
|
| 99.2 | Press Release, dated February 23, 2017 |
About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Recent Trading Information
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) closed its last trading session up +0.55 at 26.05 with 457,797 shares trading hands.